Search Results

BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital Upsized and over-subscribed Series A total funding of $44 million secured Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging disease targets

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to use in cancer, immunology and other applications.

Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities.

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and Novartis.

Integral Molecular announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and therapeutic antibodies.

Molecular Templates, Inc. today provided an update on its clinical-stage programs.